Incidence of Thrombotic Cardiovascular Events in Patients Taking Celecoxib Compared with Those Taking Rofecoxib

This publication has 13 references indexed in Scilit:

• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
  New England Journal of Medicine, 2005
• Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
  Annals of Internal Medicine, 2005
• Arthritis Medicines and Cardiovascular Events—“House of Coxibs”
  JAMA, 2005
• Merck withdraws arthritis drug worldwide
  BMJ, 2004
• Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
  Circulation, 2004
• Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?
  Drug Safety, 2004
• Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib**The investigators had full access to the data and complete control over the design, conduct analysis, interpretation, and description of the study. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or in writing the report. The views expressed are those of the investigators alone.
  The American Journal of Cardiology, 2003
• Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study
  The Lancet, 2002
• The New Zealand intensive medicines monitoring programme in pro-active safety surveillance
  Pharmacoepidemiology and Drug Safety, 2000